Osteomyelitis — infection of the bone — is one of the most consequential complications of a diabetic foot ulcer. When a chronic wound extends to underlying bone, the risk of poor healing, recurrent infection, and lower-extremity amputation rises sharply. Yet diabetic foot osteomyelitis (DFO) remains notoriously difficult to diagnose and, historically, has been treated with prolonged courses of antibiotics whose necessity is now being reconsidered. Recent guidelines and clinical trials have refined how the condition is identified and how long it needs to be treated. This article summarizes the current evidence for clinicians, patients, and caregivers.
Why Osteomyelitis Is Easy to Miss
Bone infection in the diabetic foot rarely announces itself with dramatic symptoms. Peripheral neuropathy blunts pain, and impaired immune and vascular responses can mute the classic signs of infection. As a result, osteomyelitis often hides beneath an unremarkable-looking ulcer. Clinicians are taught to raise their suspicion when an ulcer is large, deep, or long-standing, when it overlies a bony prominence, or when a toe becomes diffusely red and swollen — the so-called “sausage toe.” Because no single finding is definitive, the 2023 IWGDF/IDSA guidelines recommend combining several inexpensive, bedside-accessible assessments before turning to advanced imaging.
Bedside and Laboratory Assessment
The probe-to-bone test
The probe-to-bone test is a simple maneuver in which a sterile blunt metal probe is gently advanced through the ulcer; contact with a hard, gritty surface suggests exposed bone. A systematic review by Lam and colleagues found a pooled sensitivity of about 87% and specificity of about 83%, making a positive test in a high-risk patient strongly suggestive of osteomyelitis and a negative test in a low-risk patient reasonably reassuring.
Plain radiographs and inflammatory markers
The 2023 guidelines advise pairing the probe-to-bone test with plain X-rays and inflammatory markers such as erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Early bone infection may not appear on X-ray for one to two weeks, so a normal initial film does not exclude the diagnosis; repeat imaging or serial markers can help. A markedly elevated ESR in the setting of a non-healing ulcer adds meaningful diagnostic weight.
When Imaging Is Needed
When the diagnosis remains uncertain after clinical, radiographic, and laboratory assessment, the guidelines recommend magnetic resonance imaging (MRI). A meta-analysis by Lauri and colleagues comparing imaging modalities reported that MRI correctly identified the large majority of patients with and without bone infection, with sensitivity above 90% in most analyses. Positron emission tomography (FDG-PET) showed slightly lower sensitivity but higher specificity, making it a useful alternative when MRI is contraindicated or when avoiding false-positive results is a priority. Regardless of imaging findings, a bone sample obtained for culture and histology remains the reference standard, and bone specimens are more reliable than soft-tissue swabs for identifying the responsible organism and guiding antibiotic selection.
Rethinking How Long to Treat
For decades, DFO was treated with antibiotic courses of three months or longer. That practice has been steadily challenged. In a randomized trial, Tone and colleagues found that six weeks of antibiotics produced remission rates comparable to twelve weeks in nonsurgically treated patients, while reducing drug exposure and side effects. A later randomized pilot trial by Gariani and colleagues went further, reporting that three weeks of therapy after surgical debridement was non-inferior to six weeks, with similar remission and adverse-event rates.
Reflecting this evidence, the 2023 IWGDF/IDSA guidelines recommend approximately six weeks of antibiotic therapy for osteomyelitis managed without bone resection, and as little as three weeks when infected bone is largely removed through minor amputation or debridement. The guidelines also note that in selected patients — typically those with forefoot involvement, adequate blood flow, and no exposed bone — antibiotics alone may achieve remission without surgery.
Key Takeaways
Diabetic foot osteomyelitis is a serious but manageable complication when recognized early. Current evidence supports a stepwise diagnostic approach that begins with the probe-to-bone test, plain X-rays, and inflammatory markers, reserving MRI for uncertain cases and bone biopsy as the definitive standard. On the treatment side, the trend is toward shorter, better-targeted antibiotic courses — roughly six weeks without bone resection and about three weeks after surgical removal of infected bone. These refinements aim to control infection while limiting the harms of prolonged antibiotic use, and they underscore the value of coordinated care in preventing amputation.
References
Senneville É, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Diabetes/Metabolism Research and Reviews; 2024. (Also published in Clinical Infectious Diseases, 2023.)
Lam K, van Asten SAV, Nguyen T, La Fontaine J, Lavery LA. Diagnostic Accuracy of Probe to Bone to Detect Osteomyelitis in the Diabetic Foot: A Systematic Review. Clinical Infectious Diseases. 2016;63(7):944–948.
Lauri C, Tamminga M, Glaudemans AWJM, et al. Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET. Diabetes Care. 2017;40(8):1111–1120.
Tone A, Nguyen S, Devemy F, et al. Six-Week Versus Twelve-Week Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study. Diabetes Care. 2015;38(2):302–307.
Gariani K, Pham TT, Kressmann B, et al. Three Weeks Versus Six Weeks of Antibiotic Therapy for Diabetic Foot Osteomyelitis: A Prospective, Randomized, Noninferiority Pilot Trial. Clinical Infectious Diseases. 2021;73(7):e1539–e1545.
Comments
